Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales

Key Facts

• Here is what Merck reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per share: $2.07 adjusted vs. $1.88 expected Revenue: $15.78 billion vs. $15.20 billion expected The company posted a net income of $4.76 billion, or $1.87 per share, for the first quarter.
• Merck raked in $15.78 billion in revenue for the quarter, up 9% from the same period a year ago.
• The company recorded charges of $246 million related to restructuring in the first quarter, which are excluded from its adjusted results.
• Merck also reported a jump in sales of Gardasil, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S.

Click To Read Full Article